Evidence map›Paper›PMID 42620485›Full record

ArticleResearch square2026

Incidence, Predictors, and Outcomes Associated with Recurrent Neonatal Acute Kidney Injury in Preterm Infants: A Secondary Analysis of the Preterm Erythropoietin Neuroprotection Trial (PENUT).

Katherine Vincent, Austin D Rutledge, Tara Beck, Matthew C Gillen, Russell Griffin, Aadil Kakajiwala, Semsa Gogcu, Thomas Forbes, Michelle Starr, Judit Kiss and 4 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Katherine VincentMedical University of South Carolina.ORCID 0009-0006-0037-2738
Austin D RutledgeMedical University of South Carolina.
Tara BeckUniversity of Pittsburgh Medical Center Health System: University of Pittsburgh Medical Center.
Matthew C GillenEmory University School of Medicine.
Russell GriffinUniversity of Alabama at Birmingham.
Aadil KakajiwalaChildren's National Medical Center: Children's National Hospital.
Semsa GogcuBrown University.
Thomas ForbesRoyal Children's Hospital Research Institute: Murdoch Childrens Research Institute.
Michelle StarrRiley Hospital for Children: Riley Hospital for Children at Indiana University Health.
Judit KissUniversity of Szeged: Szegedi Tudomanyegyetem.
Shina MenonStanford University School of Medicine.
David T SelewskiMedical University of South Carolina.
Cara L SlagleRiley Hospital for Children: Riley Hospital for Children at Indiana University Health.
Heidi J SteflikMedical University of South Carolina.

Funding

Preterm Epo Neuroprotection Trial (PENUT Trial) CCCU01NS077953 · NINDS · UNIVERSITY OF WASHINGTON · PI JUUL, SANDRA E · 2013 to 2018
$10.7M
Recombinant Erythropoietin for Protection of Infant Renal Disease(REPAIReD)R01DK103608 · NIDDK · SEATTLE CHILDREN'S HOSPITAL · PI ASKENAZI, DAVID JOSEPH, GOLDSTEIN, STUART L · 2014 to 2019
$3.0M
Preterm Epo Neuroprotection Trial (PENUT Trial) DCCU01NS077955 · NINDS · UNIVERSITY OF WASHINGTON · PI HEAGERTY, PATRICK J · 2013 to 2018
$1.5M
NIDDK NIH HHS R01 DK103608NINDS NIH HHS U01 NS077953NINDS NIH HHS U01 NS077955
6 · The paper itself

Abstract

Background: Recurrent neonatal acute kidney injury (rAKI) may increase morbidity and mortality but remains understudied. We aimed to determine the incidence, risk factors, and clinical outcomes associated with rAKI in extremely low gestational age newborns (ELGANs), hypothesizing that rAKI would be associated with worse outcomes than no AKI or single AKI (sAKI). Methods: We performed a secondary analysis (ALMOND study) of the multicenter Preterm Erythropoietin Neuroprotection (PENUT) Trial conducted from 2013-2016. AKI was diagnosed retrospectively using modified neonatal Kidney Disease: Improving Global Outcomes serum creatinine criteria. Outcomes included length of stay (LOS), bronchopulmonary dysplasia (BPD), mortality, and chronic kidney disease (CKD) and hypertension (HTN) at 2 years. Comparisons among no AKI, sAKI, and rAKI groups used multivariable generalized estimating equation regression and Cox proportional hazards models. Results: Among 923 ELGANs, 211 (23%) developed rAKI. Risk factors included younger gestational age, lower birthweight, small for gestational age, lower Apgar scores, patent ductus arteriosus, severe sepsis, nephrotoxic medication exposure, hypotension, BPD, and necrotizing enterocolitis (all

Indexed as

Extremely low gestational age newbornsKDIGONeonatal acute kidney injuryNeonatal outcomesPrematurityRecurrent acute kidney injury

Identifiers

PMID42620485
PMCPMC13484859

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.